Mitsui, Rohto Pharmaceutical take 86% stake in Eu Yan Sang for S$687 million
Add BT as a preferred source
JAPAN’S Mitsui & Co and Rohto Pharmaceutical have purchased an 86 per cent stake in Eu Yan Sang International for S$687 million in cash.
In a statement on Thursday (Apr 4), Tower Capital Asia announced that its investment holding company, Righteous Crane Holding (RCH), Temasek Holdings subsidiary Blanca Investments, as well as some members of the Eu family were selling the combined stake in the company.
The deal values 100 per cent of Eu Yan Sang at about S$800 million. It was delisted from the Singapore Exchange in October 2016 at a valuation of around S$269 million in a deal with RCH.
Tower Capital Asia said that two members of the Eu Family will roll over about 10 per cent of their interest in the company and become shareholders of the consortium to provide guidance.
Eu Yan Sang chairman Richard Eu thanked Tower Capital Asia and Temasek for “transforming Eu Yan Sang into a leading natural health and wellness enterprise”, and welcomed the company’s new shareholders.
The transaction is subject to regulatory approvals and is expected to close by June 2024.
Eu Yan Sang was founded in 1879 and currently operates over 170 retail outlets and 30 traditional Chinese medicine clinics in places such as Singapore, Hong Kong and Malaysia. It also has a network across 29 markets and has manufacturing capabilities in Malaysia and Hong Kong.
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Malaysian tycoon Vincent Tan’s sell-downs point to pruning rather than an exit plan
OCBC rolls out AI-native banking, to hire 600 relationship managers in wealth push
Three Holland Village shophouses sold for S$70 million to Tat Lee Bank’s Goh family unit
The billion-dollar question Singapore Airlines shareholders should ask during its AGM
